Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

A very interesting article posted here was is the

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154897
(Total Views: 1107)
Posted On: 11/15/2020 7:42:59 AM
Avatar
Posted By: TechGuru
A very interesting article posted here was is the one carried out in Asturias Spain, as if we needed further proof that Leronlimab might be beneficial in COVID, one can ask the question: if the CCR5 receptor occupancy plays a therapeutic role, can’t we expect less patients with the CCR5-Δ32 variant to be sick with COVID?

This is exactly what this study attempted. Approximately 1% of Europeans are D32-homozygotes, and carriers of this variant would be expected to have a reduced inflammatory response and hence be hospitalized with COVID

The study was based on 294 patients who required hospitalization due to COVID-19and 460 population age-matched controls. The main finding of the study was a significantly lower frequency of CCR5-D32 among the COVID-19 patients (p=0.002). But more importantly, the largest reduction (frequency) was observed in those that were severe (ICU-group) !!!

The conclusion is then that LL should work for both M/M and S/C but we could expect a good benefit on the latter group.

Obviously this study is with a reduced number of patients (294) with a population were deletion occurs in 1%, however the much less frequency of deletion encountered in the COVID patients is very telling.

Copying from the paper:

Quote:
A polymorphism in the LZTFL1 gene located in the chemokine-receptor gene cluster (chromosome 3p) has been associated with the risk of developing COVID-19. The chemokine receptor-5 (CCR5) maps to this region, and the common 32 bp deletion variant (D32) has been associated with the extent of inflammatory disease and the outcome in several viral diseases.



So, this yet another confirmation that our drug will very likely have a positive benefit in COVID-19. We need the numbers presto !!!!

https://www.medrxiv.org/content/10.1101/2020....20224659v1


(12)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us